Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Revenue (2022 - 2025)

Historic Revenue for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $98000.0.

  • BioXcel Therapeutics' Revenue fell 5420.56% to $98000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $752000.0, marking a year-over-year decrease of 6695.96%. This contributed to the annual value of $2.3 million for FY2024, which is 6420.29% up from last year.
  • BioXcel Therapeutics' Revenue amounted to $98000.0 in Q3 2025, which was down 5420.56% from $120000.0 recorded in Q2 2025.
  • In the past 5 years, BioXcel Therapeutics' Revenue registered a high of $1.1 million during Q2 2024, and its lowest value of -$1.6 million during Q2 2022.
  • In the last 4 years, BioXcel Therapeutics' Revenue had a median value of $214000.0 in 2024 and averaged $187600.0.
  • In the last 5 years, BioXcel Therapeutics' Revenue soared by 304285.71% in 2023 and then plummeted by 8913.04% in 2025.
  • BioXcel Therapeutics' Revenue (Quarter) stood at $238000.0 in 2022, then skyrocketed by 57.98% to $376000.0 in 2023, then dropped by 2.66% to $366000.0 in 2024, then tumbled by 73.22% to $98000.0 in 2025.
  • Its Revenue was $98000.0 in Q3 2025, compared to $120000.0 in Q2 2025 and $168000.0 in Q1 2025.